Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

386884

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what progress has been made on setting up a study to image amyloid deposition in systemic amyloidosis using hybrid positron emission tomography-magnetic resonance imaging; where the study is located; how many patients have been recruited; when the study is expected to complete its initial work; and where the results will be published.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL993
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>This is a single centre study at University College London Hospital. It has now been set up and one patient has been recruited and scanned. The current planned date for end of recruitment is 1 October 2016. It is anticipated that the data will be analysed and submitted for publication in a peer reviewed journal within a year of the end of recruitment.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 14/07/2015 15:36:20 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386885

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Multiple Myeloma
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government when they expect the National Institute of Health Research Technology Assessment programme to publish initial findings from its assessment of the benefits of antibiotic prophylaxis and its effect on healthcare associated infections in myeloma patients.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL994
	answer	answer is ministerial correction date of answer 09/07/2015 answer text <p>This trial is led by the University of Birmingham. The project is recruiting ahead of schedule and expects to reach its target of 800 in the near future. The target was to do so by the end of November 2015. Publication of initial findings is expected in 2017.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 09/07/2015 13:00:57 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386886

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis and Multiple Myeloma
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether they will place in the Library of the House any publications resulting from the phase 3 clinical trials approved for the potential treatment of systemic amyloidosis or multiple myeloma; and what is the National Institute of Health Research’s assessment of progress in these areas.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL995
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL996 HL997 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386887

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether there are currently any trials for systemic amyloidosis in humans being conducted by the National Institute of Health Research charities or the commercial sector.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL996
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL995 HL997 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386888

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL997
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL995 HL996 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386891

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neural Tube Defects
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is the latest information they have regarding high risk groups suffering neural tube defects at birth.
	tabling member printed	Lord Rooker
	uin	HL1000
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>Information on high risk groups suffering neural tube defects at birth is not collected centrally.</p><p> </p><p> </p><p> </p><p>There are no current mechanisms in place for monitoring the take-up of advice given on the NHS Choices website about preventing spina bifida.</p><p> </p><p> </p><p> </p><p>The British Isles Network of Congenital Anomaly Registers (BINOCAR) collects information about the mother and child, including postcode of residence, mother’s age, pregnancy length, pregnancy outcome, when and how the anomaly was identified and the details of each anomaly.</p><p> </p><p> </p><p> </p><p>Information on congenital abnormalities including spina bifida, hydrocephalus and anencephaly is collected by the British Isles Network of Congenital Anomaly Registers. Data is currently available for 2009–2012.</p><p> </p><p> </p><p> </p><p>The following table shows the number of live births for years 2009-2012</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td colspan="5"><p>Number of cases, birth prevalence (per 10,000 total births) and 95% CIs according to congenital anomaly subgroup; six BINOCAR registers (coverage: 36% of births in England and Wales): 2009-2012 – Live Births</p></td></tr><tr><td><p> </p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td></tr><tr><td><p>Congenital anomaly</p><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td></tr><tr><td><p>Spina bifida</p><p> </p></td><td><p>31</p></td><td><p>53</p></td><td><p>34</p></td><td><p>44</p></td></tr><tr><td><p>Hydrocephalus</p><p> </p></td><td><p>48</p></td><td><p>85</p></td><td><p>72</p></td><td><p>84</p></td></tr><tr><td><p>Anencephalus and similar</p><p> </p></td><td><p>4</p></td><td><p>4</p></td><td><p>1</p></td><td><p>6</p></td></tr></tbody></table><p> </p><p><strong> </strong></p><p> </p><p>In line with National Institute for Health and Care Excellence guidelines, health professionals use appropriate opportunities to advise all women who may become pregnant that they can most easily reduce the risk of having a baby with a neural tube defect by taking folic acid supplements. This information is also available on the NHS Choices website.</p><p> </p><p><strong> </strong></p><p> </p><p>The Scientific Advisory Committee on Nutrition (SACN) was, however, commissioned to provide advice to government on the impact of folic acid fortification to improve the folate status of women and therefore reduce the number of pregnancies affected by neural tube defects. This built on previous advice from SACN’s predecessor the Committee on Medical Aspects of Food and Nutrition Policy in 2000. The Government is currently considering the recommendations that SACN made alongside other information sources, including the latest folate status data and expects to make an announcement on this in due course.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL1001 HL1002 HL1003 HL1004 HL1005 question first answered 14/07/2015 14:37:07 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	302 label Biography information for Lord Rooker

386892

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Spina Bifida: Health Education
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government how the take-up of advice given on National Health Service websites about preventing spina bifida is currently monitored.
	tabling member printed	Lord Rooker
	uin	HL1001
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>Information on high risk groups suffering neural tube defects at birth is not collected centrally.</p><p> </p><p> </p><p> </p><p>There are no current mechanisms in place for monitoring the take-up of advice given on the NHS Choices website about preventing spina bifida.</p><p> </p><p> </p><p> </p><p>The British Isles Network of Congenital Anomaly Registers (BINOCAR) collects information about the mother and child, including postcode of residence, mother’s age, pregnancy length, pregnancy outcome, when and how the anomaly was identified and the details of each anomaly.</p><p> </p><p> </p><p> </p><p>Information on congenital abnormalities including spina bifida, hydrocephalus and anencephaly is collected by the British Isles Network of Congenital Anomaly Registers. Data is currently available for 2009–2012.</p><p> </p><p> </p><p> </p><p>The following table shows the number of live births for years 2009-2012</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td colspan="5"><p>Number of cases, birth prevalence (per 10,000 total births) and 95% CIs according to congenital anomaly subgroup; six BINOCAR registers (coverage: 36% of births in England and Wales): 2009-2012 – Live Births</p></td></tr><tr><td><p> </p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td></tr><tr><td><p>Congenital anomaly</p><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td></tr><tr><td><p>Spina bifida</p><p> </p></td><td><p>31</p></td><td><p>53</p></td><td><p>34</p></td><td><p>44</p></td></tr><tr><td><p>Hydrocephalus</p><p> </p></td><td><p>48</p></td><td><p>85</p></td><td><p>72</p></td><td><p>84</p></td></tr><tr><td><p>Anencephalus and similar</p><p> </p></td><td><p>4</p></td><td><p>4</p></td><td><p>1</p></td><td><p>6</p></td></tr></tbody></table><p> </p><p><strong> </strong></p><p> </p><p>In line with National Institute for Health and Care Excellence guidelines, health professionals use appropriate opportunities to advise all women who may become pregnant that they can most easily reduce the risk of having a baby with a neural tube defect by taking folic acid supplements. This information is also available on the NHS Choices website.</p><p> </p><p><strong> </strong></p><p> </p><p>The Scientific Advisory Committee on Nutrition (SACN) was, however, commissioned to provide advice to government on the impact of folic acid fortification to improve the folate status of women and therefore reduce the number of pregnancies affected by neural tube defects. This built on previous advice from SACN’s predecessor the Committee on Medical Aspects of Food and Nutrition Policy in 2000. The Government is currently considering the recommendations that SACN made alongside other information sources, including the latest folate status data and expects to make an announcement on this in due course.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL1000 HL1002 HL1003 HL1004 HL1005 question first answered 14/07/2015 14:37:07 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	302 label Biography information for Lord Rooker

386893

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neural Tube Defects
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government how many live births where the child was diagnosed with spina bifida, hydrocephalus or anencephaly there have been in each of the past five years.
	tabling member printed	Lord Rooker
	uin	HL1002
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>Information on high risk groups suffering neural tube defects at birth is not collected centrally.</p><p> </p><p> </p><p> </p><p>There are no current mechanisms in place for monitoring the take-up of advice given on the NHS Choices website about preventing spina bifida.</p><p> </p><p> </p><p> </p><p>The British Isles Network of Congenital Anomaly Registers (BINOCAR) collects information about the mother and child, including postcode of residence, mother’s age, pregnancy length, pregnancy outcome, when and how the anomaly was identified and the details of each anomaly.</p><p> </p><p> </p><p> </p><p>Information on congenital abnormalities including spina bifida, hydrocephalus and anencephaly is collected by the British Isles Network of Congenital Anomaly Registers. Data is currently available for 2009–2012.</p><p> </p><p> </p><p> </p><p>The following table shows the number of live births for years 2009-2012</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td colspan="5"><p>Number of cases, birth prevalence (per 10,000 total births) and 95% CIs according to congenital anomaly subgroup; six BINOCAR registers (coverage: 36% of births in England and Wales): 2009-2012 – Live Births</p></td></tr><tr><td><p> </p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td></tr><tr><td><p>Congenital anomaly</p><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td></tr><tr><td><p>Spina bifida</p><p> </p></td><td><p>31</p></td><td><p>53</p></td><td><p>34</p></td><td><p>44</p></td></tr><tr><td><p>Hydrocephalus</p><p> </p></td><td><p>48</p></td><td><p>85</p></td><td><p>72</p></td><td><p>84</p></td></tr><tr><td><p>Anencephalus and similar</p><p> </p></td><td><p>4</p></td><td><p>4</p></td><td><p>1</p></td><td><p>6</p></td></tr></tbody></table><p> </p><p><strong> </strong></p><p> </p><p>In line with National Institute for Health and Care Excellence guidelines, health professionals use appropriate opportunities to advise all women who may become pregnant that they can most easily reduce the risk of having a baby with a neural tube defect by taking folic acid supplements. This information is also available on the NHS Choices website.</p><p> </p><p><strong> </strong></p><p> </p><p>The Scientific Advisory Committee on Nutrition (SACN) was, however, commissioned to provide advice to government on the impact of folic acid fortification to improve the folate status of women and therefore reduce the number of pregnancies affected by neural tube defects. This built on previous advice from SACN’s predecessor the Committee on Medical Aspects of Food and Nutrition Policy in 2000. The Government is currently considering the recommendations that SACN made alongside other information sources, including the latest folate status data and expects to make an announcement on this in due course.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL1000 HL1001 HL1003 HL1004 HL1005 question first answered 14/07/2015 14:37:07 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	302 label Biography information for Lord Rooker

386894

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Congenital Abnormalities
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether the postcodes of mothers of babies born with congenital abnormalities are yet available on the British Isles Network of Congenital Anomaly Registers.
	tabling member printed	Lord Rooker
	uin	HL1003
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>Information on high risk groups suffering neural tube defects at birth is not collected centrally.</p><p> </p><p> </p><p> </p><p>There are no current mechanisms in place for monitoring the take-up of advice given on the NHS Choices website about preventing spina bifida.</p><p> </p><p> </p><p> </p><p>The British Isles Network of Congenital Anomaly Registers (BINOCAR) collects information about the mother and child, including postcode of residence, mother’s age, pregnancy length, pregnancy outcome, when and how the anomaly was identified and the details of each anomaly.</p><p> </p><p> </p><p> </p><p>Information on congenital abnormalities including spina bifida, hydrocephalus and anencephaly is collected by the British Isles Network of Congenital Anomaly Registers. Data is currently available for 2009–2012.</p><p> </p><p> </p><p> </p><p>The following table shows the number of live births for years 2009-2012</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td colspan="5"><p>Number of cases, birth prevalence (per 10,000 total births) and 95% CIs according to congenital anomaly subgroup; six BINOCAR registers (coverage: 36% of births in England and Wales): 2009-2012 – Live Births</p></td></tr><tr><td><p> </p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td></tr><tr><td><p>Congenital anomaly</p><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td></tr><tr><td><p>Spina bifida</p><p> </p></td><td><p>31</p></td><td><p>53</p></td><td><p>34</p></td><td><p>44</p></td></tr><tr><td><p>Hydrocephalus</p><p> </p></td><td><p>48</p></td><td><p>85</p></td><td><p>72</p></td><td><p>84</p></td></tr><tr><td><p>Anencephalus and similar</p><p> </p></td><td><p>4</p></td><td><p>4</p></td><td><p>1</p></td><td><p>6</p></td></tr></tbody></table><p> </p><p><strong> </strong></p><p> </p><p>In line with National Institute for Health and Care Excellence guidelines, health professionals use appropriate opportunities to advise all women who may become pregnant that they can most easily reduce the risk of having a baby with a neural tube defect by taking folic acid supplements. This information is also available on the NHS Choices website.</p><p> </p><p><strong> </strong></p><p> </p><p>The Scientific Advisory Committee on Nutrition (SACN) was, however, commissioned to provide advice to government on the impact of folic acid fortification to improve the folate status of women and therefore reduce the number of pregnancies affected by neural tube defects. This built on previous advice from SACN’s predecessor the Committee on Medical Aspects of Food and Nutrition Policy in 2000. The Government is currently considering the recommendations that SACN made alongside other information sources, including the latest folate status data and expects to make an announcement on this in due course.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL1000 HL1001 HL1002 HL1004 HL1005 question first answered 14/07/2015 14:37:07 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	302 label Biography information for Lord Rooker

386895

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neural Tube Defects
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the implications for health equality of their current policy regarding the prevention of neural tube defect-affected pregnancies.
	tabling member printed	Lord Rooker
	uin	HL1004
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>Information on high risk groups suffering neural tube defects at birth is not collected centrally.</p><p> </p><p> </p><p> </p><p>There are no current mechanisms in place for monitoring the take-up of advice given on the NHS Choices website about preventing spina bifida.</p><p> </p><p> </p><p> </p><p>The British Isles Network of Congenital Anomaly Registers (BINOCAR) collects information about the mother and child, including postcode of residence, mother’s age, pregnancy length, pregnancy outcome, when and how the anomaly was identified and the details of each anomaly.</p><p> </p><p> </p><p> </p><p>Information on congenital abnormalities including spina bifida, hydrocephalus and anencephaly is collected by the British Isles Network of Congenital Anomaly Registers. Data is currently available for 2009–2012.</p><p> </p><p> </p><p> </p><p>The following table shows the number of live births for years 2009-2012</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td colspan="5"><p>Number of cases, birth prevalence (per 10,000 total births) and 95% CIs according to congenital anomaly subgroup; six BINOCAR registers (coverage: 36% of births in England and Wales): 2009-2012 – Live Births</p></td></tr><tr><td><p> </p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td></tr><tr><td><p>Congenital anomaly</p><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td></tr><tr><td><p>Spina bifida</p><p> </p></td><td><p>31</p></td><td><p>53</p></td><td><p>34</p></td><td><p>44</p></td></tr><tr><td><p>Hydrocephalus</p><p> </p></td><td><p>48</p></td><td><p>85</p></td><td><p>72</p></td><td><p>84</p></td></tr><tr><td><p>Anencephalus and similar</p><p> </p></td><td><p>4</p></td><td><p>4</p></td><td><p>1</p></td><td><p>6</p></td></tr></tbody></table><p> </p><p><strong> </strong></p><p> </p><p>In line with National Institute for Health and Care Excellence guidelines, health professionals use appropriate opportunities to advise all women who may become pregnant that they can most easily reduce the risk of having a baby with a neural tube defect by taking folic acid supplements. This information is also available on the NHS Choices website.</p><p> </p><p><strong> </strong></p><p> </p><p>The Scientific Advisory Committee on Nutrition (SACN) was, however, commissioned to provide advice to government on the impact of folic acid fortification to improve the folate status of women and therefore reduce the number of pregnancies affected by neural tube defects. This built on previous advice from SACN’s predecessor the Committee on Medical Aspects of Food and Nutrition Policy in 2000. The Government is currently considering the recommendations that SACN made alongside other information sources, including the latest folate status data and expects to make an announcement on this in due course.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL1000 HL1001 HL1002 HL1003 HL1005 question first answered 14/07/2015 14:37:07 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	302 label Biography information for Lord Rooker